Jci_page_head_homepage_01 Jci_page_head_homepage_02
Medhat Shehata, Josef D. Schwarzmeier, Martin Hilgarth, Rainer Hubmann, Markus Duechler, Heinz Gisslinger
Published in Volume 113, Issue 5
J Clin Invest. 2004; 113(5):676–685 doi:10.1172/JCI19540
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

Levels of TGF-β1 in BMP, serum, and PBP. TGF-β1 was measured by immunoassays before and after acidification to detect active (A) and total (B) TGF-β1. The levels of active and total TGF-β1 were significantly higher in HCL patients (n = 13) than in HDs (n = 10) and B-CLL patients (n = 5). *P < 0.01; **P < 0.001. (C) High expression of TGF-β1 mRNA in PBMCs of HCL patients (lanes 7–12) in comparison with HDs (lanes 1–6). (D) Overexpression of TGF-β1 mRNA in BMMCs of three HCL patients and spleen (spl.) cells of two HCL patients compared with BMMCs of three HDs and PBMCs (lanes 9 and 10) and BMMCs (lanes 11 and 12) of B-CLL patients.